Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 6/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237996 | 0.92 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL7562459 | 0.91 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL27701440 | 0.90 | RAB9A (0.73) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL7774668 | 0.87 | NPC1 (0.65) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL6819635 | 0.87 | NPC1 (0.65) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL7774579 | 0.87 | NPC1 (0.65) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL854996 | 0.86 | RAB9A (0.61) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL764568 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL10192026 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 | |
| SCHEMBL7562461 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1MAPK1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906537-B2 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2011-03-15 | — | — | US | disclosed |
| EP-1663211-B1 | AMINOTRIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7368472-B2 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | H. LUNDBECK A/S (DK) | 2008-05-06 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1578740-B1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | LUNDBECK & CO AS H (DK) | 2007-03-21 | — | — | EP | disclosed |
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | H. LUNDBECK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| CN-1761464-A | Substituted p-diaminobenzene derivatives | LUNDBECK & CO AS H (DK) | 2006-04-19 | — | — | CN | disclosed |
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | H. LUNDBECK A/S (DK) | 2006-01-19 | — | — | US | disclosed |
| EP-1613303-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. Lundbeck A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| EP-1578740-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. Lundbeck A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004082677-A1 | SUBSTITUTED P-DIAMINOBENZENE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004058739-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. LUNDBECK A/S (DK) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183791-A1 | Substituted p-diaminobenzene derivatives | ABCB1, UGT2B7, CYP2D6 | SMN1; SMN2 2951/4885ALDH1A1 112/4885MAPK1 1438/4885 |
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | PMP22, GRIN2B, AVPR1B | SMN1; SMN2 81/4885ALDH1A1 112/4885MAPK1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.